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OBJECTIVES: To model the likely impact of introducing routine
vaccination with a quadrivalent vaccine against HPV types 6, 11,
16 and 18 for 12 year old girls in Norway on relevant stakehold-
ers’ budgets over each of the ﬁrst 100 years. METHODS: An
excel-based budget impact model was developed, based on the
results of a mathematical model of the public health impact of
different immunization strategies using the quadrivalent HPV
vaccine. Natural disease history parameters were based upon
international data. Rates of HPV infection, mortality, cervical
cancer screening, treatment practice patterns and costs were
based upon Norwegian-speciﬁc data. Both routine vaccination of
12 year old girls and the additional effect of including a 5 year
catch-up vaccination program of females are modelled. The
model evaluates both the direct costs related to the vaccination
program, and cost savings due to reduced incidences of HPV-
related disease; cervical intraepithelial neoplasia (CIN), invasive
cancer and genital warts. The consequence for each stakeholder’s
budget is described: The Norwegian Institute of Public Health
(NIPH), the Norwegian Labour and Welfare Administration,
the four Regional Health Authorities, patients and employers.
RESULTS: The results are presented graphically and in tabular
form, for the various stakeholders and over time. Direct costs for
vaccination for the public payer are considerable, but are some-
what offset by savings for other stakeholders. The effect of the
vaccine on HPV 6 and 11 infections provides both earlier cost
offsets and increases them substantially. For the ﬁrst 35 years the
majority of discounted costs avoided are due to the prevention of
HPV 6 and 11 infections. CONCLUSIONS: This analysis dem-
onstrates the beneﬁt of analyzing budgetary consequences per
stakeholder, over time and for virus types covered. It is important
to model budget consequences not only from the public payer’s
perspective but also from a societal one.
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THE ECONOMIC IMPACT OF LOWER HIV
PREVALENCE ESTIMATES
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OBJECTIVES: The “AIDS epidemic update” (2007) published
by the United Nations (UN) and World Health Organization
(WHO) recently reported lowered estimates for the number of
person infected with HIV worldwide. This study examines the
economic impact of these revised ﬁgures upon the costs associ-
ated with treating patients with antiretroviral (ARV) drugs or
opportunistic infection (OI) prophylaxis. METHODS: The
annual change in the number of persons infected with HIV in
eight regions worldwide was calculated for 2006 and 2007
from the UN report. Average treatment rates were used to deter-
mine the number of patients treated with ARV or OI prophy-
laxis. The difference in the cost for treating these patients was
estimated by multiplying the average cost of treatment by the
number of patients treated. For ARVs, the average cost estimate
for 2006 (USD) included ﬁrst- and second-line drugs, lab costs,
inpatient and outpatient costs and counseling. For OI prophy-
laxis, only drug and counseling costs were included. Low- and
high-cost ranges were used to estimate drug costs. Only coun-
seling, inpatient and outpatient costs varied by region. Sensitiv-
ity analysis was conducted on key inputs. RESULTS: The
impact of 6.26 million fewer patients from 2007 to 2006 is
estimated to be a total cost saving of USD$1.08 billion, or a
16.4% reduction in treatment costs. The new estimates yield a
$952 million and a $129 million saving in annual ART and OI
prophylaxis costs, respectively, compared to the 2006 estimates.
Although the Sub-Saharan Africa region has the largest HIV
prevalence, the revised estimates had the greatest impact on the
total costs in South and South-East Asia, with a 48.7% reduc-
tion. CONCLUSIONS: The lower prevalence estimates provide
a signiﬁcant budget savings which varies greatly among regions.
Upon further analysis, using more detailed prevalence and cost
data, the savings may show even greater differences among
countries within the same region.
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OBJECTIVES: To determine costs caused by human papilloma-
virus (HPV) and to evaluate the cost-effectiveness of vaccinating
12 year old females with a quadrivalent HPV vaccine in Finland.
METHODS: A comprehensive analysis, based on Finnish
national health care, social insurance and cancer registries,
allowed to evaluate the costs associated with cervical cancers,
cervical lesions and genital warts diagnosed between 2001 and
2005 (health care costs, sick-leave compensations, disability
pensions, and loss of productivity). An incidence-based model
working in discrete time steps was developed to evaluate the
effects of HPV vaccine. The model utilised Monte Carlo simula-
tion to produce the outputs. Age-speciﬁc cervical cancer inci-
dence rates were derived from population-based cancer registries.
The model followed four cohorts of 12 year old females through
their lives and the vaccine was assumed to be 100% effective
against HPV types 6, 11, 16, 18. The analysis was performed
from health care payer and societal perspectives. Sensitivity
analyses were carried out to explore the effects of discount rates.
RESULTS: Screening and management of HPV related diseases
cost annually €50 M in Finland. Treatment of genital warts,
cervical dysplasia and cancer costs €37 M. Solely pap screening
costs €13 M. Vaccination of 12 year old females against HPV
types 6, 11, 16 and 18 would cost €6,957 per additional QALY
gained (no discounting) and €11,122/QALY (3.5% discounting
for money and 1.5% for health beneﬁts). CONCLUSIONS:
Currently HPV causes signiﬁcant health care costs for Finland.
As €50,000/QALY is generally considered to be the threshold of
cost-effective treatment in the developed countries, vaccination
of 12 years old girls against 6, 11, 16, 18 HPV types would be
an effective and economically proﬁtable method to reduce the
burden of the HPV related diseases.
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COST-EFFECTIVENESS OF CERVARIX™,A PROPHYLACTIC
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OBJECTIVES: Vaccination against human papillomavirus
(HPV) has been recommended in Spain for girls aged 11–14 years
old. Our objective was to estimate the cost-effectiveness of the
bivalent HPV-16/18 AS04 adjuvant vaccine, Cervarix™ (Glaxo-
SmithKline), in the current Spanish setting with cervical cancer
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